Cost-effectiveness model of using zoledronic acid once a year versus current treatment strategies in postmenopausal osteoporosis - 08/01/10
, Bernard Cortet b, Erick Legrand c, Xavier Bresse d, Ségolène Bisot-Locard d, Anne-Marie Vigneron d, Ariel Beresniak e, f
Corresponding author. Tel.: +33 3 22 66 82 50; fax: +33 3 22 66 82 59.Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 5 |
| Iconographies | 1 |
| Vidéos | 0 |
| Autres | 0 |
Abstract |
Objectives |
To compare effectiveness, associated cost of outcomes and cost-effectiveness of a single annual infusion of zoledronic acid versus current treatment strategies plans for postmenopausal osteoporosis in France.
Methods |
Twelve simulation-based models were built to investigate three types of fractures: vertebral (VF), non-vertebral excluding hip (NVF) and hip (HF), comparing two groups: zoledronic acid and current postmenopausal antiosteoporotic treatment strategies. Two effectiveness comparability assumptions have been tested: specific agent efficacy values, and same standard efficacy values for all active agents. Direct medical costs included drug costs, medical visits, monitoring and fracture management. Adherence levels were integrated into the model under the assumption that non-adherent patients had treatment effects similar to the levels of placebo effectiveness.
Results |
Using the most conservative assumption (same standard efficacy values for all active agents), zoledronic acid strategy results in less vertebral, non-vertebral and hip fractures than other current antiosteoporotic treatment options over 3 years: 12.04% vs. 14.18%, 10.61% vs. 11.28% and 2.82% vs. 4.64% respectively, (p<0.001). In addition, zoledronic acid is more cost-effective than the current treatment strategies in all types of fractures (p<0.001): 1497€ vs. 1685€ per VF avoided, 1337€ vs. 1404€ per NVF avoided and 1216€ vs. 1323€ per HF avoided.
Conclusion |
Zoledronic acid is a cost-effective treatment strategy regardless of fracture type or effectiveness comparability assumptions.
Le texte complet de cet article est disponible en PDF.Keywords : Adherence, Cost-effectiveness, Modelling, Postmenopausal osteoporosis, Zoledronic acid
Plan
Vol 77 - N° 1
P. 53-57 - janvier 2010 Retour au numéro
Article précédent
- Effects of 14 weeks of TNF alpha blockade treatment on lipid profile in ankylosing spondylitis
- Sylvain Mathieu, Jean-Jacques Dubost, Anne Tournadre, Sandrine Malochet-Guinamand, Jean-Michel Ristori, Martin Soubrier
- Effectiveness of a semi-intensive multidisciplinary outpatient rehabilitation program in chronic low back pain
- Christophe Demoulin, Stéphanie Grosdent, Lucile Capron, Marco Tomasella, Pierre-René Somville, Jean-Michel Crielaard, Marc Vanderthommen
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?